Trials / Completed
CompletedNCT00689338
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 216 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anidulafungin | Anidulafungin Intravenous Administration |
| DRUG | Fluconazole | Oral Administration of Fluconazole |
| DRUG | Voriconazole | Oral Administration of Voriconazole |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-06-03
- Last updated
- 2011-05-30
- Results posted
- 2011-05-17
Locations
61 sites across 19 countries: Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Russia, Slovakia, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00689338. Inclusion in this directory is not an endorsement.